Drugs / Minzasolmin
Minzasolmin
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06533475 | Sep → Nov 2024 | — | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 1 | NCT05845645 | May 2023 → Apr 2024 | — | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 1 | NCT04875962 | May 2019 → Feb 2020 | Parkinson disease | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05543252 | Aug 2022 → Mar 2025 | Parkinson disease | UCB Biopharma SRL | Terminated | No outcome recorded |
| Phase 2 | NCT04658186 | Dec 2020 → Sep 2024 | Parkinson disease | UCB Biopharma SRL | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Minzasolmin | “Minzasolmin (UCB0599) is an orally bioavailable and brain-penetrant small molecule ASYN misfolding inhibitor in clinical development as a disease-modifying therapeutic for...” PMID 37460603 ↗ Jul 20233“Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599).” PMID 38110790 ↗ Dec 2023 |
| Known as | DLX-313 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095072 ↗ |
| Known as | Minzasolmina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095072 ↗ |
| Known as | Minzasolmine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095072 ↗ |
| Known as | UCB0599 | “Minzasolmin (UCB0599)” NCT05543252 ↗ |
| Action | Inhibit | “small molecule ASYN misfolding inhibitor” PMID 37460603 ↗ Jul 2023 |
| Modality | Small molecule | “an orally bioavailable and brain-penetrant small molecule ASYN misfolding inhibitor” PMID 37460603 ↗ Jul 2023 |
| Route | Oral | “Route of administration: Oral use” NCT04658186 ↗ |